Introduction {#S1}
============

Comorbidity Between GAD and Depression {#S1.SS1}
--------------------------------------

Generalized anxiety disorder (GAD) and unipolar depression are the two psychological disorders most frequently seen in primary care and outpatient mental health services ([@B103]). The lifetime prevalence of GAD is considered to be between 4 and 7% ([@B45]; [@B104]), whereas for depression, the estimate reaches 16% ([@B46]), although there is high variability across cultures ([@B47]). Both disorders lead to considerable disability, with depression alone being considered the first cause of disability worldwide ([@B105]).

Both GAD and depression are considered to be chronic disorders. On the one hand, GAD is known to be a very chronic condition, with episode duration commonly averaging a decade or longer ([@B45]) and with less than 20% of sufferers experiencing complete remission of their symptoms when not seeking treatment actively ([@B103]). On the other hand, although the episode duration of depression is considerably shorter than in GAD, the recurrence of episodes is very high, with at least 50% of individuals who recover from the first one having more in their lifetime ([@B52]). The percentage of recurrence increases to 80% after a history of two depressive episodes ([@B11]).

The comorbidity between GAD and depression is more the rule than the exception ([@B48]), with studies estimating it at up to 80% of the cases ([@B44]; [@B53]). This comorbidity is associated with slower recovery and greater chronicity, recurrence rates, health costs, hospitalization rates, disability days, suicide attempts, and psychosocial disability ([@B41]; [@B103]). Additionally, depression and GAD are both relevant risk factors for the development of medical conditions such as vascular and pulmonary disease, lipid disorders, and asthma ([@B41]; [@B51]). The average annual cost of comorbid GAD and depression is about 4,235 USD per person and, when other somatoform disorders are developed, such as pain disorders, it increases to 12,624 USD ([@B106]). Importantly, the presence of comorbid GAD and depression has predicted poorer therapeutic outcomes using psychotropic medication ([@B96]) and psychological therapy ([@B61]; [@B14]).

Brief Interventions for GAD and Depression {#S1.SS2}
------------------------------------------

There are at least two main reasons to emphasize the need for developing effective, brief interventions for comorbid GAD and depression. Firstly, premature psychotherapy termination is a frequent phenomenon in most clinical settings ([@B40]; [@B91]). For instance, the review conducted by [@B67] found that between 40 and 55% of clients terminated the treatment between the first and second sessions. Other studies have found that the average number of sessions completed varies between four and six ([@B64]), and the modal number of sessions was only one ([@B10]). Importantly, there is some evidence indicating that clients who terminated therapy prematurely have similar outcomes to the individuals who never began the therapy ([@B89]). Secondly, developing brief interventions is essential because psychological therapy provided in primary care settings for depression and GAD is usually brief due to the limited budget in mental health care or because health professionals opt to attend patients for brief, time-limited therapy to improve access to mental health services for all patients in the clinic ([@B82]; [@B90]; [@B70]).

The need for developing effective, brief interventions has been strongly emphasized within the concept of "minimal intervention needed for change" or MINC. This concept refers to "the minimal level of intervention intensity, expertise, and resources needed to achieve a clinically significant improvement" ([@B31], p. 26). Accordingly, it is crucial to develop brief psychological interventions that can be realistically adopted in mental health services. However, the data of the efficacy of brief interventions obtained so far is not especially encouraging for comorbid GAD and depression. For instance, the meta-analysis conducted by [@B12] revealed that, although brief interventions provided in primary care had similar efficacy than longer treatments for anxiety disorders, the effect sizes obtained for depression and mixed anxiety and depression were considerably smaller (*d* = 0.33 and 0.26, respectively). Therefore, there seems to be ample space for improving the efficacy of brief psychological interventions for comorbid depression and anxiety disorders.

Common Transdiagnostic Processes Between GAD and Depression {#S1.SS3}
-----------------------------------------------------------

A promising way to advance in the direction of developing psychological interventions based on the concept of MINC is to analyze the transdiagnostic processes involved in GAD and depression. In this sense, the high comorbidity between GAD and depression might be due to sharing some transdiagnostic processes such as worry ([@B7]), rumination ([@B62]), and experiential avoidance ([@B37]). According to prospective and experimental studies, worry and rumination play a crucial role in the onset and maintenance of GAD and depression ([@B32]; [@B22]). Whereas excessive worry is a core characteristic of GAD ([@B7]), rumination plays a significant role in depression ([@B62]). Due to the similarity between worry and rumination and the fact that individuals with GAD show high levels of rumination, and individuals with depression high levels of worry, the term repetitive negative thinking (RNT; [@B32]; [@B22]) has been proposed to include both processes. Some therapeutic approaches aim to reduce engagement in unconstructive RNT, such as metacognitive therapy (MCT; [@B101]) and rumination-focused cognitive-behavioral therapy (RF-CBT; [@B100]).

Functionally, worry and rumination can be conceptualized as experiential avoidance (EA) strategies. EA is a central construct in acceptance and commitment therapy (ACT; [@B36]; [@B102]). It consists of a verbal regulation strategy involving deliberate efforts to avoid and escape from discomforting private experiences, even at the cost of behaving inconsistently with one's values and goals ([@B37]). EA strategies may take multiple topographies, but all pertain to the same functional class of behavior to the extent that they are directed at reducing discomfort. Empirical evidence supports the role of EA in the onset and maintenance of emotional disorders such as GAD and depression ([@B71]; [@B9]; [@B72]).

RNT-Focused ACT {#S1.SS4}
---------------

A recent approach has explicitly integrated RNT and EA within a therapeutic approach called RNT-focused ACT ([@B79], [@B74]). This approach is an attempt to provide ACT with a more in-depth focus on relational frame theory (RFT; [@B35]) by incorporating recent theoretical and empirical analysis of its clinical applications ([@B79], [@B73]). Specifically, this approach includes, among others, (a) the RFT conceptualization of psychological flexibility ([@B94]), (b) the conceptualization of values and triggers for RNT as hierarchical networks of positive and negative reinforcers ([@B29]), (c) a temporal specification of experiential avoidance cycles ([@B79]), (d) an RFT conceptualization of RNT ([@B73]), (e) and the theoretical and empirical analysis of the relational processes involved in defusion, self-as-context, and values components and metaphors (e.g. [@B57]; [@B99]; [@B86]; [@B93]; [@B30]; [@B54]; [@B16]). For the sake of brevity, we will focus the exposition on the first four points.

The RNT-focused ACT approach highlights that values are hierarchical reinforcers, or higher-order meaning functions ([@B56]), established in the individual's learning history ([@B5]; [@B58]). For instance, as indicated in [@B29], [Figure 1](#F1){ref-type="fig"} (right panel) depicts a hierarchical relational network of reinforcers in which the individual established that a "meaningful life" consists of developing friendships characterized by trust and sharing and enjoying literature by increasing knowledge and developing writing skills. Within each branch of the hierarchy, some objectives and actions acquire reinforcing functions because they are connected to the previously mentioned values. Similarly, the individual will derive a relational network in an opposite relation with the first one, which will be the "other side of the coin" of values ([@B29]).

![Example of a hierarchical network of positive reinforcers **(left)** and negative reinforcers that might function as triggers for engaging in RNT **(right)**.](fpsyg-11-00356-g001){#F1}

For example, sharing a problem with a friend might have a reinforcing function, even when the person is re-experiencing negative feelings while telling it because it is part of developing intimate friendships. In contrast, events indicating an opposite result will acquire aversive functions. For instance, when being ignored by a friend, the person might derive the aversive thought, "I can't trust him," which is hierarchically related in opposition to the value of developing intimate friendships. The most important thing is that the individual will react in the presence of this thought with a particular aim.

[@B94] identified two main ways of responding to our own behavior. The first way is responding in coordination with the immediate discriminative or controlling functions of the thought. This way, when the thought is aversive, the reaction will have a function of avoidance. For example, the person might respond by yelling at the friend for not paying attention to the conversation or by ruminating about the friend's behavior in an attempt to understand him. The second way is responding in hierarchy with the deictic "I," which means discriminating that the thought is just a momentary event and to respond under the control of values (e.g. politely asking the friend why he is not paying attention). This pattern of behavior consisting of responding in hierarchy with the deictic "I" and redirecting attention to values is the basis of psychological flexibility, which is the main aim of ACT.

Throughout most learning histories, RNT usually becomes the predominant and first reaction in coordination to aversive experiences due to the sophisticated human's linguistic abilities. In other words, individuals learn to react in less impulsive ways by engaging in RNT in order to reduce the discomfort caused by the thoughts and emotions ([@B15]). However, [Figure 2](#F2){ref-type="fig"} shows that RNT usually has a paradoxical effect because it prolongs negative affect as it focuses on negative content ([@B22]; [@B60]; [@B79]). The prolonged negative affect usually leads the individual to engage in additional experiential avoidance strategies such as thought suppression, distraction, overeating, substance consumption, etcetera (e.g. [@B63]). These strategies usually provoke a reduction in the negative affect until new triggers for RNT surface.

![Description of a pernicious cycle of RNT and its consequences.](fpsyg-11-00356-g002){#F2}

RNT processes provoke at least three critical counterproductive effects. Firstly, the network of thoughts increases in complexity because myriads of new relations are established during the process ([@B4]). This effect facilitates the initiation of a new RNT process because more thoughts might begin to work as triggers (e.g. following [Figure 2](#F2){ref-type="fig"}, the individual might engage in RNT when experiencing the thought, "Life has no meaning"). Secondly, the derivation level of the network of thoughts is reduced because of the repetition of the thinking process. This effect provokes that the individual will engage in a similar RNT process more rapidly and with higher automaticity, which resembles the common belief of uncontrollability of the RNT process among individuals with GAD and depression (e.g. [@B101]). Lastly, relational flexibility is reduced because thoughts are usually related in the same way during the RNT process. For instance, a particular thought of the RNT chain (e.g. "Why did I believe him?") is most of the time followed by a related negative thought (e.g. "I'm so naïve"). The reduced relational flexibility provokes that the individual will experience more difficulties in disengaging from RNT by thinking in alternative ways, which resembles how these individuals tend to come back to thinking about the same thing over and over again.

In conclusion, the repetition of RNT cycles provokes that the individual's life begins to focus more on RNT and the associated experiential avoidance strategies and less on his or her values. From this standpoint, GAD and depression are usually patterns of behavior characterized by RNT under the control of private experiences related in opposition to values. Accordingly, the aim of RNT-focused ACT is to develop the skill of disrupting unconstructive RNT in response to the hierarchical triggers and redirecting attention to valued actions (i.e. behavior under the control of hierarchical positive reinforcers). Focusing the intervention on the hierarchical triggers should provoke a more rapid and generalizable effect due to how the transformation of functions through hierarchical relations works ([@B25], [@B26]; [@B29]). This means that explicitly targeting the hierarchical triggers (e.g. fear of not developing the desired friendships) should produce the transformation of functions of thought integrated into it (e.g. "I can't trust him"). However, targeting only specific thoughts contained in the hierarchical trigger might produce only a limited effect ([@B28]).

Empirical Evidence of RNT-Focused ACT {#S1.SS5}
-------------------------------------

The empirical analysis of the RNT-focused ACT approach has followed a progressive strategy. The initial studies analyzed the feasibility of very brief, RNT-focused ACT protocols in emotional problems by employing single-case experimental designs (SCEDs). In the first study, [@B79] analyzed whether a 1-session protocol was sufficient to significantly reduce RNT in participants with mild to moderate emotional suffering. Eleven individuals participated in a two-arm, randomized multiple-baseline design. During the 6-week follow-up, nine participants showed significant reductions in most of the RNT measures. The intervention obtained very large effect sizes in all RNT-related measures and emotional symptoms. [@B74] conducted a second study analyzing the effect of a 2-session, RNT-focused ACT protocol in the treatment of 10 participants suffering from moderate emotional disorders. Nine participants showed clinically significant changes in emotional symptoms, with very large effect sizes (*d* = 2.44 and 2.68).

These initial studies encouraged testing brief RNT-focused ACT protocols with problems in which psychological interventions often find difficulties in reaching the usual level of efficacy. [@B76] analyzed the efficacy of a 3-session protocol in three participants diagnosed with GAD, who indicated that the couple relationship was the main worry domain. The intervention obtained very a large effect size in reducing pathological worry (*d* = 3.19), and the three participants showed clinically significant changes. Similarly, [@B81] conducted a non-concurrent, multiple-baseline design with nine children with the main diagnosis of child depression and applied a 3-session protocol. No participant showed the diagnosis of child depression or comorbid disorders at the 4-week follow-up.

Aim of the Study {#S1.SS6}
----------------

This study aims to build upon previous studies by testing the efficacy of the 3-session, RNT-focused ACT protocol used in [@B76] in participants suffering from comorbid GAD and depression. As previously discussed, testing the efficacy of brief approaches to treat comorbid GAD and depression is especially relevant due to the high prevalence of this comorbidity and the high disability, health risks, and economic costs that it provokes. A delayed multiple-baseline design was conducted with six adult participants who showed clinically significant levels of depression and GAD symptoms and at least severe symptom level in one of the disorders. The reporting of this SCED follows the SCRIBE statement ([@B92]).

Materials and Methods {#S2}
=====================

Participants {#S2.SS1}
------------

The recruitment was conducted through advertisements in social media that included the following questions: "Do you spend too much time distressed about the past or the future? Do you want to be more focused on the things that are important to you?" Seventy-six individuals responded to the advertisements and answered an online survey. Initial inclusion criteria were: (a) being older than 18 years; (b) stating that they had experienced emotional difficulties for at least 12 months, (c) stating that symptoms significantly interfered in at least three life domains out of 8 (family, friendships/social relationships, training, work, couple relationship, leisure time, health, and spirituality), and (d) presenting severe scores in depression or anxiety according to the Depression Anxiety and Stress Scale -- 21 (see the Outcome measures section). The interference of the emotional symptoms on life domains was measured by asking participants: "Please, select the life domains in which your sadness or anxiety is affecting your life." The initial exclusion criterion was being in psychological or psychiatric treatment, including psychotropic medication.

Sixty-three potential participants were rejected according to the initial inclusion and exclusion criteria: five individuals were younger than 18 years, 19 were entangled with thoughts, memories, and worries for less than 1 year (they were invited to an alternative study if they experienced these problems for at least 6 months), 7 were receiving psychological or psychiatric treatment, and 32 did not show severe scores on depression and/or anxiety (they were invited to an alternative study). Of the remaining 13 potential participants, 5 did not respond to emails or did not attend the informative session. In conclusion, eight participants met the initial inclusion criteria and attended an interview conducted by a psychologist who had received extensive training in psychological assessment.

In this interview, the terms and conditions of the study were explained. Subsequently, the interviewer explored the presence of symptoms of GAD and depression based on the Mini International Neuropsychiatric Interview (MINI; [@B85]). The interviewer also asked questions related to the course of the emotional difficulties (e.g. How much time have you been feeling this way? How has feeling this way has affected your life? Have you been in psychological or psychiatric treatment? Have you experienced suicidal thoughts?). If the GAD and depression criteria were met, participants were asked to respond to two screening measures: the Personal Health Questionnaire -- 9 (PHQ-9, [@B50]), which assesses depression, and the Generalized Anxiety Disorder -- 7 (GAD-7, [@B88]), which assesses GAD. To participate in the study, individuals had to show clinically significant levels of depression and GAD symptoms (i.e. scores of at least 10 points in both the PHQ-9 and GAD-7) and a score of at least 15 points in the PHQ-9 or GAD-7. The latter score is the cutoff for the labels of "moderately severe" in the PHQ-9 and "severe" in the GAD-7 (note that the GAD-7 does not have the label "moderately severe"). Exclusion criteria were: (a) having suicidal thoughts more than half the days according to Item 9 of the PHQ-9; and (b) reporting frequent use of illegal drugs (e.g. marijuana, cocaine, etc.). Two participants were excluded: one because of experiencing suicidal thoughts more than half the days and one because of using illegal drugs frequently. Excluded participants were given the opportunity to receive immediate treatment or were directed to a mental health service. Participants who completed the study were remunerated with 25,000 Colombian pesos (approximately 8 United States dollars) as compensation for the intensive measurement carried out in the study.

The final sample consisted of 6 participants (2 men, mean age = 31.7, *SD* = 11.5). [Table 1](#T1){ref-type="table"} shows demographic data of the participants, details of the problem, and the score range on the PHQ-9 and GAD-7. Pseudonyms are used throughout the manuscript. Participants showed a range of affected life areas between 4 and 6 and a problem duration between 4 and 25 years. Four participants had received psychological treatment in the past. Five of the six participants obtained severe scores on the PHQ-9 (*M* = 18.0, *SD* = 4.8). Likewise, five of the six participants obtained severe scores on the GAD-7 (*M* = 17.0, *SD* = 3.4).

###### 

Demographic data, problem details, and scores on depression and generalized anxiety disorder.

  **Participant**   **Sex**   **Age**   **Level of education**   **Life areas affected**   **Duration of the problem (years)**   **Previous therapy**                                                                        **PHQ-9**          **GAD-7**
  ----------------- --------- --------- ------------------------ ------------------------- ------------------------------------- ------------------------------------------------------------------------------------------- ------------------ -------------
  Amelie            F         19        Under-graduate           5                         6                                     Yes (public speaking fear)                                                                  19 (Mod. Severe)   17 (Severe)
  Annie             F         33        Graduate                 6                         4                                     Yes (drug abuse and psychoanalysis to improve self-knowledge)                               25 (Severe)        21 (Severe)
  Marylin           F         29        Technician               4                         10                                    Yes (hospitalized for severe depression and suicide attempt; suffering from fibromyalgia)   17 (Mod. Severe)   11 (Mod.)
  Julia             F         34        Technician               4                         4                                     No                                                                                          19 (Mod. Severe)   16 (Severe)
  Joaquin           M         52        Graduate                 5                         25                                    Yes (severe depression and anxiety)                                                         18 (Mod. Severe)   18 (Severe)
  Mateo             M         23        Under-graduate           4                         10                                    No                                                                                          10 (Mod.)          19 (Severe)

Mod. = Moderate.

Design and Variables {#S2.SS2}
--------------------

The design of this study was a delayed multiple-baseline design across participants. The independent variable was the staggered introduction of a 3-session, RNT-focused ACT protocol. Following [@B49], the minimum number of data points for the baseline was set at five. The protocol was implemented weekly. Afterward, a 12-week follow-up was conducted. Dependent variables were divided into outcome and process measures. As the main aim of this study was to explore the effect of the ACT protocol on treating comorbid depression and GAD, the outcome measures were scores on emotional symptoms (depression, anxiety, and stress) and pathological worry. Process measures were scores on experiential avoidance, cognitive fusion, valued living, and perseverative thinking. Since only one intervention was tested and the dependent measures were measured though automatic emails on the Internet, blinding procedures were not implemented.

Outcomes Measures {#S2.SS3}
-----------------

### Depression Anxiety and Stress Scales -- 21 {#S2.SS3.SSS1}

Depression Anxiety and Stress Scales -- 21 \[DASS-21; [@B55]; Spanish version by [@B77]\]. The DASS-21 evaluates the negative emotional states experienced during the last week through 21-items with a 4-point Likert-type scale (3 = *applied to me very much or most of the time*; 0 = *did not apply to me at all*). The Spanish version of the DASS-21 has a hierarchical factor structure with three first-order factors (Depression, Anxiety, and Stress) and a second-order factor that is an overall indicator of emotional symptoms. The DASS-21 showed good internal consistency in Colombia, with Cronbach's alphas of 0.93, 0.88, 0.83, and 0.83 for the DASS-Total, DASS-Depression, DASS-Anxiety, and DASS-Stress, respectively.

### Penn State Worry Questionnaire -- 11 {#S2.SS3.SSS2}

Penn State Worry Questionnaire -- 11 \[PSWQ-11; [@B59]; Spanish version by [@B75]\]. The PSWQ is a measure of GAD-type worry. It consists of 11 items with a 5-point Likert-type scale (5 = *very typical of me*; 1 = *not at all typical of me*). The PSWQ-11 possesses excellent internal consistency in Colombia, with a Cronbach's alpha of 0.95.

Process Measures {#S2.SS4}
----------------

### Acceptance and Action Questionnaire -- II {#S2.SS4.SSS1}

Acceptance and Action Questionnaire -- II \[AAQ-II; [@B6]; Spanish version by [@B80]\]. The AAQ-II is a general measure of experiential avoidance and is one of the most used measures of ACT processes. It consists of seven items with a 7-point Likert-type scale (7 = *always true*; 1 = *never true*). The AAQ-II showed excellent psychometric properties in Colombia (Cronbach's alpha of 0.91).

### Cognitive Fusion Questionnaire {#S2.SS4.SSS2}

Cognitive Fusion Questionnaire \[[@B27]; Spanish version by [@B78]\]. The CFQ is a general measure of cognitive fusion, and, together with the AAQ-II, it is one of the most frequently used measures of ACT processes. It consists of seven items with a 7-point Likert-type scale (7 = *always true*; 1 = *never true*). The CFQ showed excellent psychometric properties in Colombia (Cronbach's alpha of 0.93).

### Perseverative Thinking Questionnaire {#S2.SS4.SSS3}

Perseverative Thinking Questionnaire (PTQ; [@B23]). The PTQ is a content-independent measure of the tendency to engage in RNT when facing negative experiences or problems. It consists of 15 items with a 4-point Likert-type scale (4 = *almost always*; 0 = *never*). The PTQ has excellent internal consistency, high re-test reliability, and convergent and predictive validity. Preliminary data from our laboratory indicate that the PTQ possesses excellent internal consistency in Colombia (mean Cronbach's alpha of 0.96).

### Valuing Questionnaire {#S2.SS4.SSS4}

Valuing Questionnaire (VQ; [@B87]; Spanish version by Ruiz et al., submitted). The VQ is a measure of valued living averaged across life during the past week. It consists of 10 items with a 7-point Likert-type scale (6 = *completely true*; 0 = *not at all true*) and has two subscales: Progress and Obstruction. The Spanish version showed good psychometric properties in Colombia (Cronbach's alphas of 0.83 and 0.82 for Progress and Obstruction, respectively).

Screening Measures {#S2.SS5}
------------------

### Personal Health Questionnaire -- 9 {#S2.SS5.SSS1}

Personal Health Questionnaire -- 9 (PHQ-9; [@B50]). The PHQ-9 is a screening and severity measure of depression according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders -- IV-TR (DSM-IV-TR; [@B1]). It consists of a 9-item with a 4-point Likert-type scale (3 = *nearly every day*; 0 = *not at all*). The ranges for mild, moderate, moderately severe, and severe are scores of 5--9, 10--14, 15--19, and 20--27, respectively. We used the Spanish translation of the PHQ-9 for Colombia distributed by Pfizer, which showed good psychometric properties in initial studies in our laboratory with clinical (α = 0.86) and non-clinical samples (α = 0.89), and a one-factor structure.

### Generalized Anxiety Disorder -- 7 {#S2.SS5.SSS2}

Generalized Anxiety Disorder -- 7 (GAD-7; [@B88]). The GAD-7 is a screening and severity measure of GAD according to the diagnostic criteria of the DSM-IV-TR ([@B1]). It consists of 7 items with a 4-point Likert-type scale (3 = *nearly every day*; 0 = *not at all*). The score ranges for mild, moderate, and severe levels of GAD are 5--9, 10--14, and 15--21, respectively. We used the Spanish translation of the GAD-7 for Colombia distributed by Pfizer, which showed good psychometric properties in initial studies in our laboratory with clinical (α = 0.87) and non-clinical samples (α = 0.90), and a one-factor structure.

RNT-Focused ACT Protocol {#S2.SS6}
------------------------

The 3-session RNT-focused ACT protocol was the same used in [@B76]. The first session had a duration of approximately 90 min, and the second and third sessions lasted about 60 min. The protocol was based on the conceptualization of psychological flexibility in RFT terms ([@B58]; [@B94]) and aimed at developing the ability to discriminate ongoing triggers for worry/rumination, take distance from them (i.e. defusion), and behave according to what is most important at that moment for the individual in the long term (i.e. values).

The complete description of the protocol is available at <https://bit.ly/2rq5Vps> ([Supplementary Presentations S1](#SM2){ref-type="supplementary-material"}, [S2](#SM3){ref-type="supplementary-material"}). The aims of Session 1 were: (a) to present the rationale of the intervention, (b) to identify the main triggers to engage in RNT and the experiential avoidance strategies associated with RNT, (c) to promote realizing the pernicious effect of engaging in RNT and related experiential avoidance strategies, and (d) to promote the identification of the RNT process and to train in defusion. The aims of Session 2 were: (a) to review the advances since the first session, (b) multiple-exemplar training in identifying triggers for RNT and defusing from them using deictic, hierarchical framing and regulatory functions, and (c) to identify further valued actions to engage in as an alternative to engaging in RNT. Lastly, the aims of Session 3 were: (a) to review the advances since the second session, (b) values clarification through several experiential exercises, (c) to plan committed action, and (d) to close the intervention. Sessions 1 and 2 were the same as the protocol used in [@B74], with the exception that Session 1 in this study had a more extensive introduction of the intervention rationale and included explicit interactions consisting of framing ongoing behavior in hierarchy with the deictic "I."

During the intervention, participants received five audio files (30 min approximately) to practice what was worked on during the sessions daily. The audio file provided at the end of Session 1 aimed at developing the skill to notice the difference between engaging and not engaging in RNT and letting the triggers be, while choosing to behave in a valued direction. Participants were given three audio files at the end of Session 2, similar to the three first exercises conducted: (a) the centering/defusion exercise, (b) the free association exercise, and (c) the "daydreaming and worrying exercise." At the end of Session 3, participants received an additional audio file with a values exercise that summarized the content of this session.

All sessions were videotaped to analyze protocol integrity. Two independent observers with training in RNT-focused ACT protocols were given a complete version of the protocol. They were asked to review the sessions and identify if the therapist addressed the content of the epigraphs of the three sessions. Both observers indicated that the protocol was followed accurately in all cases.

Procedure {#S2.SS7}
---------

The study was implemented in the Clinical Psychology laboratory of a Colombian university. The Institutional Ethics Committee approved the procedures of the study. The self-report described above were administered online through Typeform^[1](#footnote1){ref-type="fn"}^. Participants who met the initial inclusion criteria were invited to an assessment and informative session led by the third author. When the individuals met the final inclusion criteria, the study functioning was introduced, and all informed consents were signed (all individuals agreed to participate). Afterward, participants responded to the first baseline evaluation. Participants provided baseline data every week for four weeks. The recruitment process was prolonged for 2 months, but the study began for the participants as soon as they attended the informative session and signed the informed consent. The latter decision was made for two reasons: (a) the limited number of potential participants due to the relatively restrictive inclusion criteria, and (b) ethical considerations regarding the severity of the participants' psychological disorders. During the baseline, participants were monitored every week. It was determined with the participants that, if they experienced an extraordinary increase in emotional difficulties, the baseline would be finished, and the intervention would begin immediately.

The Theil-Sen slope ([@B83]) was computed at the end of the baseline collection with each participant to explore whether there were statistically significant tendencies during the baseline. All participants were scheduled to initiate the protocol implementation because there were no significant tendencies in the baselines for the outcome measures. The protocol was introduced weekly and in an individual format. During the intervention, participants were also assessed every week during the intervention and every 2 weeks during the 3-month follow-up. The first author, who is an experienced ACT therapist and has served as a therapist in other ACT studies, implemented the protocols in all cases.

After conducting the 3-month follow-up, participants were invited to an interview to close the study. In this interview, they were offered additional intervention if necessary and were explicitly asked if they received additional therapeutic support (e.g. psychotropic medication or psychotherapy) during the follow-up. No participant felt that it was necessary to receive further sessions, and none of them received additional therapeutic support during the follow-up. When finishing this interview, participants were compensated for their participation in the study.

Data Analysis {#S2.SS8}
-------------

The raw data of this study are accessible at <https://bit.ly/2D9YvcG> ([Supplementary Data Sheet S1](#SM1){ref-type="supplementary-material"}). Before implementing the interventions, participants' baselines in primary outcome variables (DASS-Total and PSWQ) were graphed to explore scores' stability and trends (see [Figure 3](#F3){ref-type="fig"}). Scores on the PSWQ were quite stable across baselines (Participants 3 and 6 showed slight deteriorating and improvement trends, respectively). In contrast, more variability was present in the baseline of the DASS-21 scores (only Participant 6 showed a slight deteriorating trend). Although the presence of variability is not ideal, it is frequent in clinical datasets. However, variability is only an issue if it does not permit the observation of the intervention effect ([@B34]). This was not the case in the current study.

![Participants' evolution in emotional symptoms and pathological worry across the study.](fpsyg-11-00356-g003){#F3}

The data analyses conducted in this study are similar to the ones described in detail in [@B74]. Accordingly, we will only present a summary of them. The non-parametric Theil-Sen slope ([@B83]; [@B97]) was computed using the online calculator provided by [@B98] to assess the presence of statistically significant trends in the baseline. No statistically significant trends in outcomes were found in baselines (if that were the case, the participant would have received the intervention, but his or her data would be excluded from the study). After collecting all data of the study, a bottom-up analysis of single-case experimental designs (SCED) was conducted ([@B66]). After introducing the intervention, the data showed significant change levels and/or improvement trends. Most scores reached stability at the last three follow-up observations. Accordingly, we computed the within-participant statistical analyses taking into account all baseline data and only the last three follow-up points.

We selected the JZS + AR Bayesian hypothesis testing for SCED ([@B19], [@B20]) to analyze the within-participant results. The JZS + AR Bayesian model accounts for the serial dependence typical of SCEDs with an autoregressive \[AR(1)\] model. This method yields a *Bayes factor* (*B*~*ar*~) that quantifies the relative evidence in the data for the hypothesis of intervention effect (i.e. the true means of both phases differ: *B~*ar*~* \> 1) and for the hypothesis of no intervention effect (i.e. the true mean in the baseline equals the true mean in the intervention phase: *B*~*ar*~ \< 1). According to [@B43], Bayes factors are interpreted with the following ranges: 1 = No evidence of treatment effect; 1--3 = Anecdotal evidence of treatment effect; 3--10 = Substantial evidence of treatment effect; 10--30 = Strong evidence of treatment effect; 30--100 = Very strong evidence of treatment effect; and 100 = Extreme evidence of treatment effect. Values of *B*~*ar*~ lower than one are interpreted similarly but in favor of the hypothesis of no treatment effect.

The JZS + AR model estimates two main parameters: (a) an effect size that it is named δ and consists of standardizing the difference in true means between phases; and (b) a parameter called *b* for the lag 1 (*ð*) autocorrelation. As in [@B74], we selected a Cauchy distribution with *r* = 1 for δ and *b* = 5 for the lag 1 autocorrelation and conducted sensitivity analysis ([@B24]) that investigated the robustness of the results with *r* values of 0.5 and 2.0 (see [Supplementary Table S1](#TS1){ref-type="supplementary-material"}). The BayesSingleSub R package ([@B20]) was used to compute these analyses. Since previous studies showed a high degree of efficacy of RNT-focused ACT protocols ([@B79], [@B74]), we computed a one-sided Bayes factor that tested the null hypothesis that δ = 0 against the alternative hypothesis that δ \> 0. According to [@B18], a clinically significant change requires a *B*~*ar*~ \> 3 and crossing a cutoff point in the last follow-up measure that places the participant closer to the mean of the functional population than to the clinical one.

The between-case standardized mean difference effect size for SCED was computed to obtain overall estimates of the effect size of the intervention for each dependent variable at the 12-week follow-up ([@B69]). This d-statistic was derived from statistical theory and has known distribution, standard error, and significance test. Importantly, this effect-size measure is in the same metric as the Cohen's d used in between-groups, randomized designs (see the mathematical developments in [@B38], [@B39]; [@B69]). This statistical method models single-case data with a hierarchical linear model, uses restricted maximum likelihood estimation, takes into account the autocorrelation typical in SCED, and corrects small sample bias using Hedges' *g*. Three or more participants are necessary to compute this method in multiple-baseline designs. The d-statistic for SCED was computed according to the guidelines provided by [@B95] using the R package scdhlm ([@B68]). As this method accounts for potential trends in both the baseline and intervention, all data were used to compute the d-statistic. Standard guidelines suggest that values of *d* between 0.20 and 0.49 represent a small effect size, values between 0.50 and 0.79 represent a medium effect size, and values of 0.80 or higher represent large effect sizes ([@B13]).

Results {#S3}
=======

Within-Participant Results {#S3.SS1}
--------------------------

[Figure 3](#F3){ref-type="fig"} shows the evolution of the scores on the outcome measures. There were no significant trends in the baselines. The visual analysis shows that the ACT protocol was effective in decreasing emotional symptoms (DASS-21 total scores) and pathological worry (PSWQ scores) in all participants. For the sake of space, the figures corresponding to the process measures can be accessed at <https://osf.io/d9cyp/> ([Supplementary Figures S1](#FS1){ref-type="supplementary-material"}--[S5](#FS5){ref-type="supplementary-material"}). Only one statistically significant trend was found for Amelie in AAQ-II scores according to the Theil-Sen slope analysis. Visual inspection shows that the intervention was effective in decreasing experiential avoidance, cognitive fusion, and RNT in all participants. Regarding the measures of valued living, the intervention was visually effective for five participants in the VQ-Progress, and all participants in the VQ-Obstruction.

[Table 2](#T2){ref-type="table"} shows the main results of the JZS + AR Bayesian model. Five out of 6 participants showed at least substantial evidence of an intervention effect according to Bayes factors in overall emotional symptoms (i.e. DASS-total scores), whereas all participants showed substantial evidence in pathological worry (i.e. PSWQ scores). All participants showed evidence for an intervention effect in experiential avoidance (i.e. AAQ-II scores), cognitive fusion (i.e. CFQ scores), and repetitive negative thinking (i.e. PTQ scores). Lastly, 2 and 3 participants showed at least substantial evidence of change in values progress (i.e. VQ-Progress) and obstruction (i.e. VQ-Obstruction), respectively.

###### 

Results of the JZS + AR analysis and clinically significant change for each participant and measure with a prior distribution of *r* = 1.

                                                   **Amelie**   **Annie**   **Marylin**   **Julia**   **Joaquin**   **Mateo**
  ------------------------------------ ----------- ------------ ----------- ------------- ----------- ------------- -----------
  **Primary outcome measures**                                                                                      
  DASS -- Total (emotional symptoms)   δ           8.6          2.6         1.0           1.3         3.3           6.6
                                       *B*~*ar*~   \>**100**    **14.5**    2.1           **3.2**     **31.7**      \>**100**
                                       *CSC*       **YES**      **YES**     NO            **YES**     **YES**       **YES**
  PSWQ (pathological worry)            δ           11.0         7.6         7.2           2.7         4.0           4.2
                                       *B*~*ar*~   \>**100**    \>**100**   \>**100**     **17.8**    **73.5**      **73.1**
                                       *CSC*       **YES**      **YES**     **YES**       **YES**     NO            **YES**
  **Secondary outcome measures**                                                                                    
  AAQ-II (experiential avoidance)      δ           7.7          4.5         3.7           2.6         2.9           3.0
                                       *B*~*ar*~   \>**100**    **80.1**    **44.5**      **16.2**    **23.5**      **24.9**
                                       *CSC*       **YES**      NO          **YES**       **YES**     NO            **YES**
  CFQ (cognitive fusion)               δ           23.9         5.9         2.1           2.7         2.6           3.0
                                       *B*~*ar*~   \>**100**    \>**100**   **9.5**       **16.7**    **15.5**      **22.3**
                                       *CSC*       **YES**      **YES**     **YES**       **YES**     NO            **YES**
  PTQ (perseverative thinking)         δ           5.8          5.1         4.2           5.2         7.1           2.4
                                       *B*~*ar*~   \>**100**    \>**100**   **80.6**      \>**100**   \>**100**     **12.3**
                                       *CSC*       **YES**      **YES**     **YES**       **YES**     NO            **YES**
  VQ -- Progress values                δ           8.6          0.9         0.3           0.2         3.5           0.1
                                       *B*~*ar*~   \>**100**    2.0         0.8           0.6         **39.6**      0.5
                                       *CSC*       **YES**      NO          NO            NO          **YES**       NO
  VQ -- Obstruction values             δ           2.5          1.7         0.6           1.0         2.2           0.6
                                       *B*~*ar*~   **11.5**     **5.6**     1.2           2.0         **9.8**       1.2
                                       *CSC*       **YES**      **YES**     NO            NO          **YES**       NO

B

ar

= Bayes Factors of the JZS + AR model. B

ar

\> 1 supports the hypothesis of intervention effect. B

ar

\> 3 are in bold to highlight where at least substantial evidence of treatment effect was found.

[Table 2](#T2){ref-type="table"} also shows the results of clinically significant change (CSC) in outcome and process measures. Concerning primary outcome measures, 5 out of 6 participants showed CSC in DASS-total and PSWQ. Also, 5 of 6 participants showed CSC in CFQ and PTQ. For the AAQ-II scores, 4 of 6 participants showed CSC. Lastly, 2 and 3 participants showed CSC in VQ-Progress and VQ-Obstruction, respectively.

Across-Participant Results {#S3.SS2}
--------------------------

[Figure 4](#F4){ref-type="fig"} shows the mean results across participants in all the variables of the study. The mean scores for baselines were computed by averaging the scores of all participants in the first week, second week, third week, and so. Horizontal, dashed lines represent the mean scores of non-clinical samples in Colombia for each measure. At posttreatment, participants showed scores similar to the non-clinical samples in most of the measures. Most changes were observed at posttreatment, but participants continued improving during the 3-month follow-up. Overall, the changes in the outcomes and process measures took place simultaneously.

![Mean scores on outcome and process measures across the study.](fpsyg-11-00356-g004){#F4}

[Table 3](#T3){ref-type="table"} shows the mean scores in all measures during baseline, posttreatment, and 6-, and 12-week follow-ups. Standardized mean differences for SCED were very large at posttreatment on the primary outcomes (DASS-Total: *d* = 2.16, DASS-Depression: *d* = 1.45, DASS-Anxiety: *d* = 1.47, DASS-Stress: *d* = 2.28, PSWQ: d = 2.69), but the effect sizes were higher at the 3-month follow-up (DASS-total: *d* = 3.34, DASS-Depression: *d* = 2.37, DASS-Anxiety: *d* = 1.90, DASS-Stress: *d* = 3.49, PSWQ: *d* = 4.52). Effect sizes were also very large for process measures at the 3-month follow-up (AAQ-II: *d* = 3.46; CFQ: *d* = 3.90; PTQ: *d* = 4.52; VQ-Progress: *d* = 0.92; VQ-Obstruction: *d* = 1.98).

###### 

Means and standard deviations of each self-report measure at baseline, posttreatment, 6- and 12-week follow-ups, and effect sizes at posttreatment and 12-week follow-up.

                                              **Baseline**   **Post**        **6-week F-U**   **12-week F-U**   ***d*-statistic for SCED [Post treatment]{.ul}**   ***d*-statistic for SCED [12-w F-U]{.ul}**                 
  ------------------------------------------- -------------- --------------- ---------------- ----------------- -------------------------------------------------- -------------------------------------------- ------------- --------------
  **Primary outcomes**                                                                                                                                                                                                        
  DASS-Total: Emotional symptoms              37.17 (6.94)   12.17 (6.37)    7.17 (3.60)      5.83 (5.04)       2.16 (0.47)                                        \[1.3, 3.1\]                                 3.34 (0.76)   \[2.0, 4.9\]
  DASS -- Depression                          13.60 (4.06)   5.33 (2.94)     2.50 (2.07)      2.00 (2.53)       1.45 (0.40)                                        \[0.8, 2.3\]                                 2.37 (0.78)   \[1.1, 4.0\]
  DASS -- Anxiety                             9.67 (3.70)    1.83 (2.32)     1.00 (1.10)      1.17 (1.47)       1.47 (0.43)                                        \[0.7, 2.3\]                                 1.90 (0.62)   \[0.9, 3.2\]
  DASS -- Stress                              13.90 (2.28)   5.00 (2.83)     3.67 (2.07)      2.67 (2.50)       2.28 (0.50)                                        \[1.4, 3.3\]                                 3.49 (0.74)   \[2.2, 5.0\]
  PSWQ: Pathological worry                    45.17 (3.49)   31.83 (8.33)    28.00 (8.56)     24.67 (7.47)      2.69 (0.95)                                        \[1.0, 4.6\]                                 4.52 (0.98)   \[2.8, 6.6\]
  **Secondary outcomes (process measures)**                                                                                                                                                                                   
  AAQ-II: Experiential avoidance              37.57 (4.71)   21.83 (6.55)    18.67 (9.07)     17.17 (10.26)     2.06 (0.67)                                        \[0.9, 3.4\]                                 3.46 (0.80)   \[2.1, 5.1\]
  CFQ: Cognitive fusion                       39.87 (4.10)   23.33 (8.82)    18.33 (8.69)     16.67 (11.18)     2.32 (0.60)                                        \[1.3, 3.6\]                                 3.90 (0.91)   \[2.3, 5.8\]
  PTQ: Perseverative thinking                 46.37 (4.01)   25.67 (11.59)   19.33 (9.48)     17.83 (8.80)      3.27 (0.91)                                        \[1.6, 5.1\]                                 4.52 (0.90)   \[3.0, 6.4\]
  VQ: Valued living -- Progress               13.50 (7.03)   22.17 (3.82)    19.00 (6.81)     21.67 (4.13)      0.99 (0.33)                                        \[0.5, 1.7\]                                 0.92 (0.51)   \[0.1, 0.9\]
  VQ: Valued living -- Obstruction            18.63 (3.31)   11.17 (2.56)    9.33 (2.58)      7.17 (5.27)       1.44 (0.34)                                        \[0.8, 2.1\]                                 1.98 (0.49)   \[1.1, 3.0\]

AAQ-II = Acceptance and Action Questionnaire -- II; CFQ = Cognitive Fusion Questionnaire; DASS = Depression, Anxiety, and Stress Scales -- 21; PSWQ = Penn State Worry Questionnaire; PTQ = Perseverative Thinking Questionnaire; SCED = Single-case experimental design; VQ = Valuing Questionnaire.

Discussion {#S4}
==========

The comorbidity between GAD and depression is very high, especially in primary care settings, and has been associated with greater chronicity, recurrence rates, health costs, and psychological disability ([@B41]; [@B103]; [@B106]; [@B48]). Unfortunately, the presence of this comorbidity predicts poorer therapeutic outcomes ([@B96]; [@B61]; [@B14]). Specifically, the empirical evidence shows that brief interventions tested for this problem in primary care have obtained small effect sizes (e.g. [@B12]). Accordingly, developing and testing brief psychological interventions for comorbid GAD and depression is crucial because of their potential to be adopted in primary care settings, where a shorter duration of treatment is the norm ([@B70]). A promising way to advance in this direction is to focus on the transdiagnostic processes involved in these disorders, which might improve the efficiency of interventions delivered in this setting.

In recent years, research has identified several transdiagnostic processes involved in depression and GAD, including RNT and EA (e.g. [@B36]; [@B32]; [@B101]; [@B3]; [@B100]). A recent functional contextual approach has linked RNT and experiential avoidance in a model of brief intervention called RNT-focused ACT ([@B79], [@B74], [@B76]; [@B21]; [@B81]). The current study advances the evidence for the efficacy of brief RNT-focused ACT protocols in participants suffering from comorbid and severe GAD and depression. Six adults who met the criteria for both diagnoses received a 3-session RNT-focused ACT protocol. They showed stable levels of emotional symptoms and pathological worry during the 5 weeks of baseline.

To analyze clinically significant changes produced by the intervention, the Bayesian framework for SCED suggested by [@B18] was adopted. This framework is stricter than the most used method advocated by [@B42] and does not rely on the conceptual problems of *p*-values. Of the 6 participants, 5 showed CSC in both the DASS-21 and PSWQ. Most participants also showed CSC in RNT (5/6), experiential avoidance (4/6), and cognitive fusion (5/6). The standardized mean difference effect sizes for SCED were very large at the 12-week follow-up for outcome (DASS-total: *d* = 3.34; PSWQ: *d* = 4.52) and process measures (AAQ-II: *d* = 3.46; CFQ: *d* = 3.90; PTQ: *d* = 4.52). Importantly, these effect sizes share the same metric as the between-group Cohen's *d*.

The results on values measures (i.e. VQ-Progress and VQ-Obstruction) were more modest according to the JZS + AR, which indicated that only 2 participants showed CSC in progress in values and 3 participants showed CSC in obstruction in values. The effect sizes for the values measures were also the lowest ones in this study (*d* = 0.92 and 1.98 for Progress and Obstruction, respectively). These results indicate that more explicit emphasis on values can be needed to obtain effect sizes similar to the other process measures.

The effect sizes obtained in this study were very large and improved from posttreatment to the 3-month follow-up. This finding is coherent with previous studies using RNT-focused ACT protocols ([@B79], [@B74], [@B76]). The augmentation of the intervention efficacy during the follow-up period might be due to the continuous practice and increased skill in disengaging from RNT. In this sense, it is not very likely to completely stop engaging in RNT after only a few sessions. Contrarily, this skill might be improved after some weeks of daily practice during which the individual begins to discriminate the triggers and the RNT process better and to disrupt the process while focusing on valued actions. However, the design of this study does not allow us to test this hypothesis. Further research should analyze the decrease of RNT as a mediator of the effect of the intervention effect.

Some limitations of this study are worth noting. The most important limitation is that dependent variables were measured exclusively through self-reports. Accordingly, further studies might analyze the intervention effect through independent clinician-administered assessments, ecological momentary assessment, or in-session participants' behavior and verbalizations. Secondly, potential comorbidity with other emotional or personality disorders was not explored. Further studies might make use of a complete structured diagnostic interview. Thirdly, we used a delayed multiple-baseline design because of the difficulty of recruiting participants and for ethical reasons given the participants' high level of emotional symptoms. This design does not allow the same level of experimental control as concurrent multiple-baseline designs ([@B33]). However, some characteristics of this study make this limitation less relevant: (a) participants had been experiencing emotional symptoms for at least 12 months (i.e. symptoms were not momentary); (b) the 5 measurement points of baseline represent weekly measures, which indicates that the baseline showed no improvement trend across 1.5 months; and (c) maturation confounding effects are not a concern when considering adult behavior of different ages and with a very prolonged clinical problem (i.e. it is unlikely that biological or psychological processes would have had similar effects across the participants only due to the mere passage of time). Fourthly, a general limitation of SCEDs is that they lack active control conditions; thus, they do not control for the non-specific effects of therapy. Further studies should analyze the efficacy of the RNT-focused ACT protocol versus a psychological placebo. Fifthly, the design of this study did not permit us to analyze potential mediators of the effect of the intervention. In this sense, it is possible to analyze the processes of change at the individual level in SCED; however, a more intensive assessment should be conducted (e.g. [@B8]). Lastly, only one therapist implemented the ACT protocol analyzed. Further studies should include several therapists to control for the effect of the therapist's characteristics.

The effect sizes found in the current study were unusually large and contrasted with the weighted effect sizes found in a meta-analysis of the effect of cognitive behavior therapy (CBT) and ACT for major depression and GAD (e.g. [@B17]; [@B2]). However, these findings should be taken with caution because, although the metric of the d-statistic computed in this study is the same as in group designs, the effect sizes found in SCED studies are usually higher than those found in group designs such as randomized controlled trials ([@B65]; [@B84]). Overall, this study indicates that RNT-focused ACT protocols are promising for the treatment of depression and GAD and warrant conducting randomized controlled trials to compare their effect versus waiting-list control conditions or brief versions of empirically established treatments such as behavioral activation or cognitive therapy.

Conclusion {#S5}
==========

In conclusion, this study constitutes a promising step in the analysis of brief RNT-focused ACT protocols for the treatment of comorbid and severe GAD and depression. Further studies need to be conducted to establish the efficacy of this type of protocol and analyze its long-term effect. Importantly, if subsequent studies replicate the findings of this one, the RNT-focused ACT approach would be an excellent candidate to be adopted in mental health services.
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Participants' evolution in cognitive fusion across the study.
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Participants' evolution in repetitive negative thinking across the study.
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Results in the JZS+AR analysis for each participant and measure with prior distributions of *r* = 0.5, *r* = 1.0, and *r* = 2.0.
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